Medtronic (MDT) Dividend Stock Analysis: Dividend, Growth & Valuation
Medtronic plc (NYSE: MDT) is one of the world’s largest medical technology companies, developing and manufacturing medical devices across cardiovascular care, neuroscience, surgical technologies and other healthcare markets.
For dividend investors, Medtronic stands out for its long history of dividend growth and exposure to healthcare technology. However, a strong dividend record alone does not determine the quality of a stock.
This Medtronic dividend stock analysis examines the company’s business quality, competitive advantages, financial strength, dividend sustainability, risks and current valuation.
Medtronic: Key Metrics
| Metric | Current |
|---|---|
| Share Price | ~$92.77 |
| Market Cap | ~$118.7B |
| P/E (TTM) | ~22.85x |
| EPS (TTM) | ~$4.06 |
| Annual Dividend | $2.88 |
| Dividend Yield | ~3.11% |
| Payout Ratio | ~75.7% |
| FY27 Non-GAAP EPS Guidance | $5.94–$6.00 |
| Consecutive Dividend Increases | 49 years |
Market data changes continuously. The figures above are approximate and reflect market data available at the time of publication. Investors should verify the latest share price, valuation multiples and dividend yield before making financial decisions.
1. Business Quality
Medtronic operates in medical technology markets where demand for many of its products is driven by healthcare needs rather than short-term consumer trends.
The company operates across three major portfolios:
- Cardiovascular
- Neuroscience
- Medical Surgical
Its products include pacemakers, defibrillators, cardiac ablation technologies, neurosurgical systems, surgical equipment and other medical devices.
Medtronic operates at significant scale. In fiscal 2026, the company generated approximately $36.4 billion in revenue, $7.3 billion in operating cash flow and $5.4 billion in free cash flow.
The company also entered fiscal 2027 with stronger operating momentum. In the first quarter of FY27, revenue reached approximately $9.76 billion, up 13.7% year over year on both a reported and organic basis. Medtronic subsequently raised its FY27 organic revenue growth guidance to 7.25%–7.75%.
The first-quarter comparison included an additional fiscal week, which Medtronic estimated contributed approximately $570 million to revenue. This makes it important not to extrapolate the reported quarterly growth rate directly across the full fiscal year.
Overall, Medtronic combines substantial scale, a diversified medical technology portfolio and significant cash generation.
2. Competitive Advantages
Medtronic benefits from several structural characteristics that can support its competitive position.
Regulatory Barriers
Medical devices are subject to extensive regulatory requirements, clinical evaluation and approval processes. These requirements can create meaningful barriers to entry for potential competitors.
Research & Development
Innovation is central to Medtronic’s business model. The company invested approximately $2.9 billion in research and development during FY2026, supporting new products and technologies across its medical device portfolio.
Established Clinical Relationships
Medical technologies often require physician training, integration into clinical workflows and confidence in product performance.
Established relationships with healthcare providers and medical systems can therefore become an important competitive advantage.
Product Portfolio and Scale
Medtronic’s broad portfolio allows it to participate in multiple healthcare technology markets rather than depending on a single product category.
The company is also investing in newer growth platforms. During Q1 FY27, Cardiovascular revenue increased 18.9% organically, while Neuroscience and Medical Surgical increased 9.3% and 10.2%, respectively.
3. Financial Strength
Financial strength is an important part of the Medtronic dividend case.
In FY2026, the company generated approximately:
- $36.4 billion in revenue
- $7.3 billion in operating cash flow
- $5.4 billion in free cash flow
Medtronic also ended FY2026 with substantial cash and investments, supporting its ability to fund dividends, research and development, acquisitions and other capital requirements.
Current Yahoo Finance data shows approximately $8.82 billion in total cash, $5.41 billion in levered free cash flow, a total debt-to-equity ratio of approximately 55.4%, and a profit margin of roughly 13.9%.
For a dividend-focused analysis, the key question is not simply whether Medtronic generates accounting profits. It is whether the company can consistently convert those profits into sufficient cash flow to support dividends while continuing to invest in its business and manage its financial obligations.
Medtronic’s recent free cash flow generation provides an important foundation, although debt levels and payout requirements remain metrics worth monitoring.
4. Dividend Safety & Growth
Medtronic increased its quarterly dividend to $0.72 per share, equivalent to $2.88 annually.
The increase marked the company’s 49th consecutive year of dividend increases. Medtronic is also a constituent of the S&P 500 Dividend Aristocrats index.
At a share price of approximately $92.77, the annual dividend corresponds to a dividend yield of about 3.11%.
However, dividend yield is only one part of the analysis.
Yahoo Finance reports a payout ratio of approximately 75.7%, which means future dividend growth will depend in part on the company’s ability to increase earnings and maintain sufficient free cash flow.
Medtronic paid approximately $3.6 billion in dividends during FY2026 while generating approximately $5.4 billion in free cash flow.
The long dividend history is significant, but historical consistency does not guarantee the same rate of dividend growth in the future.
5. Key Risks
Slower Earnings Growth
A high-quality business can still experience periods of slower growth. Some areas of Medtronic’s portfolio operate in mature markets where maintaining high growth rates can be challenging.
Regulatory Risk
Medical devices depend on regulatory approvals and compliance requirements. Delays, additional requirements or changes in regulation can affect product launches and operating results.
Product and Technology Risk
Medical technology is highly competitive. New technologies developed by competitors can change market dynamics and put pressure on existing product categories.
Debt and Payout
Medtronic’s payout ratio remains relatively high. If earnings growth slows, the company’s capacity for rapid dividend increases could become more limited.
Currency Risk
Medtronic operates internationally, so changes in foreign exchange rates can affect financial results reported in U.S. dollars.
Valuation Risk
Even a strong dividend business can become less attractive from a valuation perspective if investors pay too much for future earnings.
This makes current valuation multiples an important part of the analysis.
6. Valuation
At the time of this analysis, Medtronic shares trade at approximately $92.77.
The stock’s trailing P/E is approximately 22.85x, based on trailing twelve-month EPS of about $4.06. Yahoo Finance also reports a forward P/E of approximately 15.48x.
However, for the Fair Value calculation, we will use Medtronic’s own FY27 non-GAAP EPS guidance rather than combining Yahoo’s forward multiple with a different earnings definition.
On September 1, 2026, Medtronic raised its FY27 diluted non-GAAP EPS guidance to $5.94–$6.00.
Using the midpoint:
FY27 EPS midpoint = $5.97
At a share price of $92.77, the market is therefore valuing Medtronic at approximately:
$92.77 ÷ $5.97 = 15.54x FY27 EPS
For the Fair Value calculation, we use a rounded 15.5x reference P/E.
Therefore:
$5.97 × 15.5 = $92.54
Estimated Fair Value: ~$92.54
This calculation is intentionally transparent.
The analysis does not use an arbitrary P/E multiple simply to produce a predetermined valuation. Instead, it uses the midpoint of management’s current FY27 EPS guidance and a valuation multiple that closely reflects the market’s current valuation of those earnings.
The resulting Fair Value of approximately $92.54 is therefore a reference valuation based on the assumptions above. It is not a forecast of the future share price and is not a Target Price.
7. 15% Margin of Safety
Income Stock Radar uses a 15% Margin of Safety as an additional valuation cushion below Fair Value.
Using the estimated Fair Value of $92.54:
$92.54 × 15% = $13.88
$92.54 × 85% = $78.66
| Valuation Metric | Value |
|---|---|
| Current Share Price | ~$92.77 |
| Estimated Fair Value | ~$92.54 |
| Price at 15% Margin of Safety | ~$78.66 |
Based on these assumptions, the current share price is approximately in line with the calculated Fair Value, while the 15% Margin of Safety level is approximately $78.66.
This level is not a Target Price, Buy Price or recommendation to purchase the stock.
It simply represents the calculated price after applying a 15% valuation cushion to the estimated Fair Value.
Income Stock Radar Framework
| Factor | What We Examine |
|---|---|
| Business Quality | Business stability, profitability and cash generation |
| Competitive Advantages | Regulatory barriers, R&D, scale and product portfolio |
| Financial Strength | Debt, cash flow, earnings and dividend funding |
| Dividend | History, sustainability and growth potential |
| Risks | Factors that could affect the business and dividend |
| Fair Value | Estimated value based on earnings and valuation assumptions |
| 15% Margin of Safety | Additional valuation cushion below Fair Value |
This framework separates business quality from valuation rather than reducing the analysis to a single score or ranking.
Conclusion
Medtronic combines a large and diversified medical technology business with significant cash generation and a 49-year history of consecutive dividend increases.
In FY2026, the company generated approximately $36.4 billion in revenue and $5.4 billion in free cash flow. Medtronic also entered FY2027 with stronger operating momentum and raised its full-year organic revenue and adjusted EPS guidance following its first-quarter results.
At approximately $92.77 per share, Medtronic trades at roughly 22.85x trailing earnings. Based on the midpoint of management’s FY27 non-GAAP EPS guidance, the current market price represents approximately 15.5x expected FY27 earnings.
Using these assumptions, the estimated Fair Value is approximately $92.54, while the 15% Margin of Safety level is approximately $78.66.
This analysis examines Medtronic’s business quality, dividend sustainability, financial strength, risks and valuation. It is not a recommendation to buy or sell the stock.
Related Dividend Analysis
- Procter & Gamble (PG) Dividend Stock Analysis
- Coca-Cola (KO) Dividend Stock Analysis
- McDonald’s (MCD) Dividend Stock Analysis
- Microsoft (MSFT) Dividend Stock Analysis
- 5 Dividend Stocks to Research This Week
Disclaimer
This article is provided for informational and educational purposes only and does not constitute investment, financial, or tax advice.
The author is not a licensed investment adviser or securities analyst. Financial data, valuation assumptions, and market conditions can change over time.
Investors should conduct their own research and independently evaluate the risks before making any financial decisions.
Income Stock Radar analyzes. We don’t tell investors what to buy or sell.
To explore more dividend research and company analysis, visit the Income Stock Radar homepage.